A PROTON PUMP INHIBITOR, E3810, HAS ANTIBACTERIAL ACTIVITY THROUGH BINDING TO HELICOBACTER-PYLORI

被引：40

作者：

HIRAI, M

AZUMA, T

ITO, S

KATO, T

KOHLI, Y

机构：

[1] Second Department of Internal Medicine, Fukui Medical School, Fukui, 910-11, Matsuoka-cho, Yoshida-gun

来源：

JOURNAL OF GASTROENTEROLOGY | 1995年 / 30卷 / 04期

关键词：

HELICOBACTER PYLORI; PROTON PUMP INHIBITOR; SCATCHARD PLOT ANALYSIS;

D O I：

10.1007/BF02347561

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Helicobacter pylori infection is causally related to atrophic gastritis, and it may also be associated with peptic ulcer and gastric carcinoma. Eradication of H. pylori is recommended in patients with such diseases, especially in those with peptic ulcer. A new potent proton pump inhibitor, E3810, had an antibacterial effect on H. pylori, as has been reported for omeprazole and lansoprazole, two other proton pump inhibitors. The minimum inhibitory concentration of E3810 was 1.57-3.13 mu g/ml, lower than that of omeprazole or lansoprazole. To clarify the mechanism of the antibacterial effect of E3810, we analyzed the characteristics of E3810 binding to H. pylori. Scatchard plot analysis of this binding showed a curvilinear profile, indicating the presence of several molecules with different affinities to E3810 on H. pylori. The binding capacity of E3810 to H. pylori was calculated to be about 2 x 10(6) sites/cell. These results suggested that E3810 has an antibacterial effect against H. pylori and that the effect may be mediated through direct binding to H. pylori.

引用

页码：461 / 464

页数：4

共 17 条

[1]

Warren J.R., Marshall B., Unidentified curved bacilli on gastric epithelium in active chronic gastritis, Lancet, 1, pp. 1273-1275, (1983)

[2]

Blaser M.J., Gastric Campylobacter-like organisms, gastritis, and peptic ulcer disease, Gastroenterology, 93, pp. 371-383, (1987)

[3]

Marshall B.J., Goodwin C.S., Warren J.R., Et al., Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori, Lancet, 2, pp. 1437-1442, (1988)

[4]

Rauws E.A.J., Tytgat G.N.J., Cure of duodenal ulcer associated with eradication of Helicobacter pylori, Lancet, 335, pp. 1233-1235, (1990)

[5]

Hentschel E., Brandstatter G., Dragosics B., Et al., Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer, N Engl J Med, 328, pp. 308-312, (1993)

[6]

Borody T., Cole P., Noonan S., Et al., Long-term Campylobacter recurrence post-eradication, Gastroenterology, 94, (1988)

[7]

Iwahi T., Satoh H., Nakao M., Et al., Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylon, Antimicrob Agents Chemother, 35, pp. 490-496, (1991)

[8]

Adamek R.J., Wegener M., Labenz J., Et al., Medium-term results of oral and intravenous omeprazole/amoxicillin Helicobacter pylori eradication therapy, Am J Gastroenterol, 89, pp. 39-42, (1994)

[9]

Fujisaki H., Shibata H., Oketani K., Et al., Effects of the proton pump inhibitor, E3810, on gastric secretion and gastric and duodenal ulcers or erosions in rats, Drug Invest, 3, pp. 328-332, (1991)

[10]

Scatchard G., Some physical chemical aspects of “plasma extenders”, Ann NY Acad Sci, 55, pp. 455-464, (1952)

← 1 2 →